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[~  Safety, tolerability and efficacy of multiple, rising doses of 
aerosolized Moli1901 in CF patients 
F. Ratjen 1,2, F. Stehling 2, K. Starke 3, H. Brunar 4, T. Laliberte 5, R. Widmann 4, 
L. Molina 5, H. Grasemann 1'2. 1Hospital for Sick Children, Toronto, Canada; 
2 Children ~' HosTital, University of Essen, Germany; 3Ruhrlandklinik Essen, 
Germany; 4AOP Pharmaceuticals', Wien, Austria; 5Lantobi Inc, USA 
Affiliation, Country 
Moli1901 activates a Ca2+-dependent alternative Cl~hannel with the potential to 
bypass dysfunctional CFTR. In this phase IIa single center, placebo controlled, 
double-blinded study we assessed safety and tolerability of Moli1901 in 3 doses 
(0.5, 1.5 and 2.5rag/d) versus placebo (normal saline) once daily for 5 days 
administered by inhalation (PARI LC Plus). Within each cohort of 8 patients, 6 
received Moli1901 and 2 placebo. Patients included were )16 years of age with 
a FEV1 > 60% predicted. Exclusion criteria were ABPA, B. cepacia infection and 
severe liver disease. The study involved 8 clinic visits over a period of 4 weeks 
to assess for adverse vents, pulmonary function tests (PFTs), O2-saturation and 
quality of life. A significant adverse vent was defined a priori as a decline of 
FEV1 ~>20% from baseline accompanied by symptoms. 3 patients (one in each 
cohort) had a decrease in FEV1 > 20% following the first inhalation. Treatment was 
discontinued in one of these patients because of wheezing; however FEV1 returned 
to baseline on the following day. Subsequent inhalations in the other two patients 
did not result in a persistent decline in FEV1. All other patients tolerated inhalation 
well. The median change FEV1 from day 1 to day 5 was 2.5% in the placebo group, 
2% in the 0.5 rag/d, 6% in the 1.5 mg/d and 7% in the 2.5 mg/d group. Although this 
trial was not primarily designed to show efficacy, the differences between treatment 
groups were significant (Kruskal-Wallis test, p 0.03). Post-hoc paired comparisons 
demonstrated a significant difference between the 2.5mg/d group and placebo 
(Wilcoxon test, p 0.01), but not for the other treatment groups. No significant 
changes were observed in other lung function parameters and O2-saturation. These 
results support he further investigation of Molil901 in CF patients. 
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1~ Denufosol tetrasodium inhalation solution: results from two 
phase 2 trials in CF patients with mild to moderate lung disease 
L. Smiley 1, A. Rossi 1 , D. Mathews 1 , J. Engels 1, A. Schaberg 1 , D. Kellerman 1 ,
C. Shaffer 1, R. Deterding 2. 1Inspire Pharmaceuticals', Inc., Durham, NC; 
2University of Colorado, Denve~ CO, USA 
Aims: Denufosol, aselective P2Y 2 receptor agonist, is designed to provide potential 
benefit o CF patients through its actions on enhancing mucociliary clearance and 
has been studied in several Phase 2 trials. 
Methods: Two 28-day, placebo-controlled, randomized, multi-center studies were 
conducted in a total of 161 CF patients. The first study enrolled patients with mild 
CF with FEV 1 ~>75% of predicted normal while the second study included patients 
with FEV 1 60%-90%. Consistent trends with respect to the benefit of denufosol as 
an early intervention treatment (i.e., in 130 patients with FEV 1 ~>75% of predicted 
normal) from these two studies is presented below. 
Results: Cough was consistently among the most frequently reported AE in 
denufosol vs placebo recipients [47% vs 52% (first study); 37% vs 29% (second 
study), respectively]. Patients treated with denufosol (active doses combined) had 
better lung function at the end of the study as compared to placebo [differences 
from placebo in percent change from baseline for FEV 1 and FEF25 % 75% were 
4.0% and 8.3% (first study); 2.4% and 5.9% (second study), respectively]. Overall, 
fewer pulmonary exacerbations were reported in the denufosol group vs placebo 
[4% vs 10% (first study); 4% vs 7% (second study), respectively]. 
Conclusions: Doses of denufosol up to 60 mg given three times daily were generally 
well tolerated. Although these studies were not designed as efficacy studies, 
denufosol had favorable ffects on lung function and exacerbation rates over 28 
days in patients with mild lung function impairment. Denufosol development will 
advance into longer term Phase 3 studies. 
I •  Inhaled dry powder mannitol (Bronchitol) improves FEV1 in 
Cystic Fibrosis 
B. Charlton 1, A. Lassig 1 , CF-201 Study Investigators 2. 1Pharmaxis Ltd, Frenchs 
Forest, NSW, Australia; 2CF-201 study sites', Australia 
Aims: Bronchitol, an osmotic agent, has been shown to increase mucociliary 
clearance. We determined the effect of 2 weeks' treatment with Bronchitol on 
lung function, efficacy and safety parameters in patients with CE 
Methods: Patients with known CF, age >8 and FEV1 40 80% predicted were en- 
rolled. The blinded, controlled, cross-over study design involved 2 weeks treatment 
with inhaled Bronchitol (420 mg bd) or control, 2 weeks washout, and then 2 weeks 
on the alternative treatment. Endpoints were FEV1 (primary), FEF25 75, FVC, 
FEV1/FVC, PEFR, QoL questionnaire (CFQ), symptom questionnaire, physical 
signs, sputum microbiology and safety profile. 
Results: Thirty nine patients of both genders and average age 19 (8 48) years 
with a baseline FEV1 of 65±13% predicted were randomized to treatment. Half 
the patients used concomitant Pulmozyme treatment. Primary endpoint: FEV1 
increased 7±2% on Bronchitol (121±33 mls) and unchanged on control (p < 0.01 
vs control). Secondary endpoints: FEF25 75 increased 15.5±5% on Bronchitol 
(0.15±0.05L/sec) and unchanged on control (p<0.01 vs control), FEV1/FVC 
ratio increased by 2.2± 1.1% on Bronchitol (p < 0.05 vs control), FVC increased 
4.6± 1.6% on Bronchitol (NS). Symptoms improved on Bronchitol compared with 
control (p < 0.05). Abnormal chest sounds improved on Bronchitol (vs control 
p < 0.05). CFQ domains were all improved on Bronchitol but did not reach statistical 
significance. The treatment effects were independent of concomitant Pulmozyme 
use. Sputum microbiology was unchanged overall on either treatment and no serious 
or significant adverse vents were related to treatment with Bronchitol. 
Conclusions: Bronchitol was well tolerated and efficacious during two weeks 
administration in patients with CE Longer term studies are warranted. 
The impact of azithromycin on moderately severe adult Cystic Fibrosis 
patients 
Z.E.K. Hoare, J.C. Dewar. Nottingham Adult CF Centre, Nottingham City Hospital 
(NCH), Nottingham, UK 
Introduction: Macrolide antibiotics are becoming an accepted anti-inflammatory treat- 
ment in Cystic Fibrosis (CF) [1 ]. The largest rial (n 185) showed asmall improvement 
in FEV1, plus a significant reduction of in-patient days and intravenous antibiotics [2]. 
Most trials have been small and so the role of macrolides remains unclear. We applied 
stringent criteria for use at the adult CF unit, NCH, in order to audit efficacy, as follows: 
FEV1 < 50%, frequent exacerbations ora rapid deterioration i clinical state. 
Methods: A retrospective audit of case notes on the first twenty patients at NCH 
commenced onazithromycin, 250 rag, thrice weekly. Impact on FEV1, BMI (body mass 
index) and number of exacerbations per 12 months was assessed. Change in FEVI% 
predicted; BMI; and number of exacerbations for 12 months pre-azithromycin and six 
months post-azithromycin were compared using a paired t-test. Potentially confounding 
factors including major changes to treatment were noted. 
Results: Population demographics: average age 29, FEV1 predicted 47%, and BMI 
19.9. There was a significant average improvement i  FEV1 predicted of 19% (p < 0.045 
CI 0.004 0.358) during the first 6 months of treatment. Average BMI improved by 4.1% 
(p 0.087 CI 0.012 0.159) and the average number of exacerbations was reduced by 
17% (p 0.118 CI 0.002 0.012). There were no adverse vents. 
Discussion: 
• Azithromycin appears to improve FEV1 and BMI, reducing infective exacerbations 
in our moderately severe patients. 
• Whilst numbers are small and data retrospective, this audit gives a clear picture of 
what is actually happening in real-time clinical practice in an adult CF unit. 
• A national trial is required to more carefully delineate the role of azithromycin in 
CE 
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